QIAGEN ROA 2010-2022 | QGEN

Current and historical return on assets (ROA) values for QIAGEN (QGEN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
QIAGEN ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $0.51B $6.15B 8.38%
2022-03-31 $0.54B $6.18B 8.86%
2021-12-31 $0.51B $6.15B 8.58%
2021-09-30 $0.60B $6.04B 10.11%
2021-06-30 $0.48B $5.91B 8.24%
2021-03-31 $0.45B $5.76B 7.91%
2020-12-31 $0.36B $5.87B 6.51%
2020-09-30 $0.19B $5.77B 3.57%
2020-06-30 $0.01B $5.30B 0.27%
2020-03-31 $-0.03B $5.18B -0.59%
2019-12-31 $-0.04B $5.24B -0.77%
2019-09-30 $-0.03B $5.14B -0.46%
2019-06-30 $0.20B $5.38B 3.59%
2019-03-31 $0.19B $5.42B 3.45%
2018-12-31 $0.19B $5.75B 3.54%
2018-09-30 $0.09B $5.30B 1.72%
2018-06-30 $0.08B $5.31B 1.50%
2018-03-31 $0.05B $5.11B 1.09%
2017-12-31 $0.04B $5.04B 0.85%
2017-09-30 $0.09B $5.10B 1.97%
2017-06-30 $0.08B $4.56B 1.76%
2017-03-31 $0.08B $4.07B 1.97%
2016-12-31 $0.08B $4.31B 1.92%
2016-09-30 $0.12B $4.33B 2.96%
2016-06-30 $0.12B $4.12B 2.97%
2016-03-31 $0.13B $4.12B 3.06%
2015-12-31 $0.13B $4.18B 3.13%
2015-09-30 $0.10B $4.16B 2.46%
2015-06-30 $0.11B $4.13B 2.44%
2015-03-31 $0.11B $4.17B 2.56%
2014-12-31 $0.12B $4.45B 2.60%
2014-09-30 $0.15B $4.46B 3.43%
2014-06-30 $0.16B $4.56B 3.65%
2014-03-31 $0.07B $4.49B 1.73%
2013-12-31 $0.07B $4.09B 1.71%
2013-09-30 $0.05B $4.06B 1.16%
2013-06-30 $0.04B $3.98B 0.87%
2013-03-31 $0.12B $4.03B 3.01%
2012-12-31 $0.13B $4.09B 3.28%
2012-09-30 $0.09B $3.96B 2.37%
2012-06-30 $0.10B $3.88B 2.53%
2012-03-31 $0.10B $3.80B 2.51%
2011-12-31 $0.10B $3.73B 2.46%
2011-09-30 $0.13B $3.95B 3.34%
2011-06-30 $0.13B $4.00B 3.38%
2011-03-31 $0.14B $3.96B 3.58%
2010-12-31 $0.14B $3.91B 3.75%
2010-09-30 $0.15B $3.89B 3.99%
2010-06-30 $0.15B $3.77B 4.08%
2010-03-31 $0.15B $3.78B 4.08%
2009-12-31 $0.14B $3.80B 4.13%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.336B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00